Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 24442245)

1.

Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems.

Cohen LE, Gordon JH, Popovsky EY, Gunawardene S, Duffey-Lind E, Lehmann LE, Diller LR.

Bone Marrow Transplant. 2014 Apr;49(4):502-8. doi: 10.1038/bmt.2013.218. Epub 2014 Jan 20.

PMID:
24442245
2.

Long-term complications in survivors of advanced stage neuroblastoma.

Laverdière C, Cheung NK, Kushner BH, Kramer K, Modak S, LaQuaglia MP, Wolden S, Ness KK, Gurney JG, Sklar CA.

Pediatr Blood Cancer. 2005 Sep;45(3):324-32.

PMID:
15714447
3.

High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.

Yalçin B, Kremer LC, Caron HN, van Dalen EC.

Cochrane Database Syst Rev. 2013 Aug 22;8:CD006301. doi: 10.1002/14651858.CD006301.pub3. Review.

PMID:
23970444
4.

Endocrine late effects from multi-modality treatment of neuroblastoma.

van Santen HM, de Kraker J, Vulsma T.

Eur J Cancer. 2005 Aug;41(12):1767-74.

PMID:
16039114
5.
6.

Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in preparation for autologous bone marrow transplantation.

Hovi L, Saarinen-Pihkala UM, Vettenranta K, Lipsanen M, Tapanainen P.

Bone Marrow Transplant. 1999 Nov;24(10):1131-6.

7.

Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma.

Hobbie WL, Moshang T, Carlson CA, Goldmuntz E, Sacks N, Goldfarb SB, Grupp SA, Ginsberg JP.

Pediatr Blood Cancer. 2008 Nov;51(5):679-83. doi: 10.1002/pbc.21683.

8.

Survival and late effects in children with stage 4 neuroblastoma.

Perwein T, Lackner H, Sovinz P, Benesch M, Schmidt S, Schwinger W, Urban C.

Pediatr Blood Cancer. 2011 Oct;57(4):629-35. doi: 10.1002/pbc.23036. Epub 2011 Feb 11.

PMID:
21319289
9.

Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology.

Flandin I, Hartmann O, Michon J, Pinkerton R, Coze C, Stephan JL, Fourquet B, Valteau-Couanet D, Bergeron C, Philip T, Carrie C.

Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1424-31. Epub 2006 Jan 19.

PMID:
16427213
10.

Late effects of treatment in survivors of childhood acute myeloid leukemia.

Leung W, Hudson MM, Strickland DK, Phipps S, Srivastava DK, Ribeiro RC, Rubnitz JE, Sandlund JT, Kun LE, Bowman LC, Razzouk BI, Mathew P, Shearer P, Evans WE, Pui CH.

J Clin Oncol. 2000 Sep 15;18(18):3273-9.

PMID:
10986060
11.

Late sequela after treatment of childhood low-grade gliomas: a retrospective analysis of 69 long-term survivors treated between 1983 and 2003.

Benesch M, Lackner H, Sovinz P, Suppan E, Schwinger W, Eder HG, Dornbusch HJ, Moser A, Triebl-Roth K, Urban C.

J Neurooncol. 2006 Jun;78(2):199-205. Epub 2006 Apr 25.

PMID:
16739030
12.

Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols.

Saha A, Salley CG, Saigal P, Rolnitzky L, Goldberg J, Scott S, Olshefski R, Hukin J, Sands SA, Finlay J, Gardner SL.

Pediatr Blood Cancer. 2014 Sep;61(9):1644-52; quiz 1653-72. doi: 10.1002/pbc.25064. Epub 2014 May 1.

PMID:
24789527
13.

N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.

Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Bénard J, Delattre O, Favrot M, Peyroulet MC, Thyss A, Perel Y, Bergeron C, Courbon-Collet B, Vannier JP, Lemerle J, Sommelet D.

J Clin Oncol. 1997 Mar;15(3):1171-82.

PMID:
9060561
14.

[Occurrence and prognostic impact of selected factors in neuroblastoma in children].

Wieczorek A, Balwierz W.

Przegl Lek. 2010;67(6):393-8. Polish.

PMID:
21344768
15.

Neuroblastoma in Turkish children: experience of a single center.

Aydn GB, Kutluk MT, Yalçn B, Büyükpamukçu M, Kale G, Varan A, Akyüz C, Senocak ME, Büyükpamukçu N.

J Pediatr Hematol Oncol. 2009 Jul;31(7):471-80. doi: 10.1097/MPH.0b013e3181a6dea4.

PMID:
19564739
16.

Late effects of treatment for germ cell tumors during childhood and adolescence.

Hale GA, Marina NM, Jones-Wallace D, Greenwald CA, Jenkins JJ, Rao BN, Luo X, Hudson MM.

J Pediatr Hematol Oncol. 1999 Mar-Apr;21(2):115-22.

PMID:
10206457
17.

Growth hormone function and treatment following bone marrow transplant for neuroblastoma.

Olshan JS, Willi SM, Gruccio D, Moshang T Jr.

Bone Marrow Transplant. 1993 Oct;12(4):381-5.

PMID:
8275038
18.

Late effects in survivors of infant leukemia.

Leung W, Hudson M, Zhu Y, Rivera GK, Ribeiro RC, Sandlund JT, Bowman LC, Evans WE, Kun L, Pui CH.

Leukemia. 2000 Jul;14(7):1185-90.

PMID:
10914540
19.

Italian cancer figures, report 2012: Cancer in children and adolescents.

AIRTUM Working Group; CCM; AIEOP Working Group.

Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225. English, Italian.

PMID:
23585445
20.

High prevalence of early hypothalamic-pituitary damage in childhood brain tumor survivors: need for standardized follow-up programs.

Clement SC, Meeteren AY, Kremer LC, van Trotsenburg AS, Caron HN, van Santen HM.

Pediatr Blood Cancer. 2014 Dec;61(12):2285-9. doi: 10.1002/pbc.25176. Epub 2014 Aug 17.

PMID:
25131941
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk